cancer treatment

“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy” Peer-Reviewed Publication Impact Journals LLC image: Figure 2: Challenges and emerging advancements in CAR-T therapy. The schematic representation outlines the major limitations associated with CAR-T treatment, including various toxicities, limited efficacy in solid tumors, on-target/off-tumor effects, hypogammaglobulinemia, time constraints and associated costs. The challenges […]

by Max Planck Society edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes Drug screening for DSB repair pathway modulators. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-67243-0 In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more than 2,000 clinically approved drugs on DNA repair and CRISPR genome editing outcomes.

by Westmead Institute for Medical Research edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes Credit: Journal of Clinical Investigation (2025). DOI: 10.1172/jci192938 A new study published in the Journal of Clinical Investigation has identified biomarkers that predict the likelihood of a patient developing checkpoint inhibitor-associated autoimmune diabetes before they are treated with immune checkpoint inhibitors. Australian researchers say identifying those at high

by Cedars-Sinai Medical Center edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes Odds ratio for aggressive treatment choice by life expectancy across race and ethnicity. Credit: Prostate Cancer and Prostatic Diseases (2025). DOI: 10.1038/s41391-025-01036-w Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or Caucasian men, according to new research by Cedars-Sinai investigators published in

by Dan Bernardi, Syracuse University edited by Stephanie Baum, reviewed by Andrew Zinin  Editors’ notes Credit: Chemical Science (2025). DOI: 10.1039/d5sc05710h Chemotherapy has long been a cornerstone of cancer treatment, but its effectiveness comes at a cost. The powerful drugs used to kill cancer cells often damage healthy tissues as well, leading to side effects ranging from nausea and fatigue

by Keck School of Medicine of USC edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Credit: Pixabay/CC0 Public Domain Chimeric antigen receptor (CAR) T cell therapy, which uses a patient’s own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have struggled to adapt the